Sources of Transfer Factor For his pioneering work on transfer factor, Dr. H. Sherwood Lawrence used an extract of human blood cells. For many years, human blood or blood harvested from farm animals and slaughterhouses remained the sole sources and were typically injected. Today, cow or goat colostrum (the milk a mother produces right after birth) or chicken eggs are recognized as the most common polyvalent sources due to their efficacy, abundance and economics. These sources are usually dried and capsulized or powdered. Transfer factors or extractions of transfer factors are still extracted from blood as well as grown in vitro. However, these sources are typically antigen-specific and reserved for research purposes due to their relative lack of economics and availability. Transfer factor preparations can include whole products or concentrated transfer factors harvested from whole products using specialized and sometimes patented microfiltration technologies. Whole Colostrum Colostrum can be dried in its original whole form and encapsulated. Sources: Natural Immune Booster: Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 1998 The Super Supplement Combination for Optimal Immune Function: Enhanced Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 2000 “A New Basis for the Immunoregulatory Activities of Transfer Factor—an Arcane Dialect in the Language of Cells,” Lawrence HS, Borkowsky W. Cell Immunol, 1983. Dorland's Illustrated Medical Dictionary. www.mercksource.com

Believe in the Product and the Science...the Success will come Naturally. The Basics of Transfer Factor Transfer factors are natural, microscopic molecules that reside in the bodies of all animals. They are messengers, passing immunity information about the presence of an immune threat—whether external or internal—and how to properly respond, from immune cell to immune cell. Transfer factors are produced by lymphocytes with cell-mediated immunity function. They carry the parent lymphocyte’s antigen-specific cell-mediated immunity (delayed-type hypersensitivity) to unsensitized, or naive, lymphocytes. They can also increase the nonantigen-specific immunostimulatory activity of the recipient lymphocytes. Transfer factors transfer immunity information—recognition of pathogens and appropriate immune response—with inducer, suppressor and antigen-specific factors. The inducer factor allows transfer factor to aid the adaptive immune response to viral infections, parasites, malignancies, bacterial and mycobacterial disease, fungal infection, autoimmune disorders and neurological disease. This factor can transfer an immune response in under 24 hours and significantly reduce or eliminate symptoms of illness. The suppressor factor keeps the immune system from over-responding, such as to pollens and other foreign bodies, as well as to itself as in the case of an autoimmune disorder. The antigen-specific factor carries critical tags that the immune system uses to identify foreign microbes and cells. Transfer factors are found in even the most primitive immune systems. As such, transfer factors’ inducer and suppressor factors are universal and can transfer immunity across species barriers. Hence, transfer factors from a cow can confer immunity in a human. The antigen-specific factor can transfer immunity between species when crossover occurs between antigen-specific pathogens, such as in smallpox and cowpox, E. coli, etc.   Sources: Natural Immune Booster: Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 1998 The Super Supplement Combination for Optimal Immune Function: Enhanced Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 2000 “A New Basis for the Immunoregulatory Activities of Transfer Factor—an Arcane Dialect in the Language of Cells,” Lawrence HS, Borkowsky W. Cell Immunol, 1983. “Structural Nature and Functions of Transfer-Factors,” Kirkpatrick CH. Annals of The New York Academy of Sciences, 1993

Who Needs Transfer Factor Anyone—healthy or diseased, with a few exceptions—benefits from regular transfer factor supplementation. The use of transfer factor has resulted in no reports of serious adverse reactions, even when clinically administered in doses in excess of normal for prolonged periods. Those with specific ailments also benefit. Numerous studies have shown the effectiveness of transfer factor in eliminating or aleviating symptoms of herpes, chronic fatigue syndrome, epstein barr, hepatitis, secondary infection due to AIDS, candida, cancer and many other disorders. Studies have also shown than continual use provides the greatest benefit with maximum immune activity occuring 24 to 48 hours after initial dosing. The need for transfer factor as an adjunct to better health stems from the growing awareness that prevention is the best source of treatment. With the increasing risks of antibiotic resistance and significant health threats, such as SARS, the medical community increasingly turns to the inherent concept of vaccines—prevention. Transfer factors are akin to vaccines. But, rather than expose the patient’s immune system to the actual disease or a deactivated version of the same, transfer factors expose the patient’s immune system to the memory of a health threat—whether foreign or native—and the knowledge of how to best respond to protect itself. Sources: Natural Immune Booster: Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 1998 The Super Supplement Combination for Optimal Immune Function: Enhanced Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 2000 “Effect of Anti-Herpes Specific Transfer Factor” Byston J., Cech K, Pekarek J, Jilkova J. Biotheraphy. 1996 “Orally Adminstered HSV-Specific Transfer Factor (TF) Prevents Genital or Labial Herpes Relapses.” Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R. Biotheraphy.1996. “Efficacy of Transfer Factor in Treating Patients with Recurrent Ocular Herpes Infections.” Meduri R, Campos E, Scorolli L, De Vince C. Pizza G, Viza D. Biotherapy. 1996. Clinical study of HSV-specific Transfer Factor on relapse HSVK. Anon. Xi’an Yike Daxue Xuebao, 1996. “Transfer Factor Prevents Relapses in Herpes Keratitis Patients, a Pilot Study.” Pizza G, Meduri R, De Vinci C, Scorolli L, Viza D. Biotherapy. 1994. “The Use of Transfer Factors in Chronic Fatigue Syndrome: Prospects and Problems,” Levine PH. Biotheraphy. 1996. “Clinical, Epidemilog and Virologic Studies in Four Clusters of Chronic Fatigue Syndrome.” Lvine PH, Jacobsen S, Pockinki AG, Cheney P, Peterson D, Connelly RR, Weil R, Ablashi DV, Salahuddin SZ, Pearson GR and Hoover R. Arc Int Med. 1992. “Inhibition of In Vitro HIV Infection by Dialyzable Leukocyte Extracts.” Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menendez de San Pedro JC, Navea L, Ojeda M, Arana MJ. Biotherapy. 1996. “Preliminary Results in HIV-1-Infected Patients Treated with Transfer Factor (TF) and Zidovudine (ZDV).” Raise E, Buerra L, Viza D, Pizza G, De Vinci C, Shiattone ML, Rocaccio L, Cicognani M, Gritti F. Biotheraphy.1996. “Dialysable Leucocyte Extract (DLE) Reduces Lipopolysaccharide-Induced Tumour Necrosis Factor Secretion in Human Leukocytes.” Ojeda Ojeda M, Fernandez Ortega CB, Arana Rosainz MJ. Biotheraphy.1996. “Transfer Factor in Chronic Mucocutaneous Candidiasis.” Masi M, De Vinci C, Baricordi OR. Biotherapy. 1996. “Treatment of Chronic Mucocutaneous Candidiasis with Transfer Factor.” Kirkpatrick CH, Greenberg LE. In: Immune Regulators in Transfer Factor. Kham A, Kirkpatrick CH, Hill NO (eds). Academic Press, 1979.  “Use of Transfer Factor for the Treatment of Recurrent Non-Bacterial Female Cystitis (NBRC): A Preliminary Report.” De Vinci C, Pizza G, Cuzzocrea D, et al. Biotheraphy.1996. “Radioprotective Effects of DLE.” Kofranek V, Barnet K, Pekarek J, Cech K. In: Research and Application of Transfer Factor and DLE. Huo B-L, Wang, R-Z, Zou Z-F (eds.) Xueyuan Press: Bejing. “The Adjuvant Therapy of Nasopharyngeal Tumor with Transfer Factor.” Sibl O, Pekarek J, Cech K, Svejcar J. In: Research and Application of Transfer Factor and DLE. Bao-Lai H, Ru-Zhang W, Zho-Fen Z (eds.) Xueyan Press: Bejing. 1989. “A Preliminary Report on the Use of Transfer Factor for Treating Stage D3 Hormone-Unresponsive Metastatic Prostrate Cancer. Pizza G, De Vinci C, et al. Biotherapy. 1996. “Transfer Factor as an Adjuvant to Non-Small Cell Lung Carcinoma (NSCLC) Therapy.” Pilotti V, et al. Biotherapy. 1996. “Adjuvant Treatment Using Transfer Factor for Bronchogenic Carcinoma: Long-Term Follow-Up.” Whyte Ri, et al. Ann  Thorac Surg. 1992. “Postoperative Immunostimulation After Complete Resection Improves Survival of Patients with Stage I Non-Small Cell Lung Carcinoma.” Fujisawa T, Yamaguchi Y. Cancer. 1996. “Transfer Factor: Clinical Usage and Experimental Studies.” A Basten and S. Croft In: Immunological Engineering Jirsch DW (ed). MTP Press Ltd., Falcon House. 1978. “Transfer Factor in Malignancy.” Pizza G, De Vinci C, Fudenberg HH. Progress in Drug Research, 1994. Blind study conducted by Dr. Anatoli Vorobiev at the Russian Academy of Medical Science.